Ganciclovir: Difference between revisions
Ostermayer (talk | contribs) (Text replacement - " pts" to " patients") |
Neil.m.young (talk | contribs) (Text replacement - " w/ " to " with ") |
||
| Line 7: | Line 7: | ||
*[[CMV]] prophylaxis, solid organ transplant | *[[CMV]] prophylaxis, solid organ transplant | ||
**IV route: 5 mg/kg IV q12h x7-14 days, then 5 mg/kg IV q24h or 6 mg/kg IV 5x/wk | **IV route: 5 mg/kg IV q12h x7-14 days, then 5 mg/kg IV q24h or 6 mg/kg IV 5x/wk | ||
**PO route: 1000 mg PO tid, give | **PO route: 1000 mg PO tid, give with food | ||
*[[CMV]] prophylaxis, HIV-assoc. | *[[CMV]] prophylaxis, HIV-assoc. | ||
**IV route: 5 mg/kg IV 5-7x/wk; Info: not 1st-line agent | **IV route: 5 mg/kg IV 5-7x/wk; Info: not 1st-line agent | ||
**PO route: 1000 mg PO tid; Info: not 1st-line agent; give | **PO route: 1000 mg PO tid; Info: not 1st-line agent; give with food | ||
*[[CMV]] retinitis, immunocompromised patients | *[[CMV]] retinitis, immunocompromised patients | ||
**Induction tx: 5 mg/kg IV q12h x14-21 days; Info: not 1st-line agent | **Induction tx: 5 mg/kg IV q12h x14-21 days; Info: not 1st-line agent | ||
**Maintenance tx, IV route: 5 mg/kg IV 5-7x/wk; Alt: 6 mg/kg IV 5x/wk; Info: not 1st-line agent | **Maintenance tx, IV route: 5 mg/kg IV 5-7x/wk; Alt: 6 mg/kg IV 5x/wk; Info: not 1st-line agent | ||
**Maintenance tx, PO route: 1000 mg PO tid; Alt: 500 mg PO q3h while awake (6 doses/day); Info: not 1st-line agent; give | **Maintenance tx, PO route: 1000 mg PO tid; Alt: 500 mg PO q3h while awake (6 doses/day); Info: not 1st-line agent; give with food | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Revision as of 13:03, 13 July 2016
Administration
- Type: Antiviral
- Routes of Administration: IV, PO
- Common Trade Names: Cytovene
Adult Dosing
- CMV prophylaxis, solid organ transplant
- IV route: 5 mg/kg IV q12h x7-14 days, then 5 mg/kg IV q24h or 6 mg/kg IV 5x/wk
- PO route: 1000 mg PO tid, give with food
- CMV prophylaxis, HIV-assoc.
- IV route: 5 mg/kg IV 5-7x/wk; Info: not 1st-line agent
- PO route: 1000 mg PO tid; Info: not 1st-line agent; give with food
- CMV retinitis, immunocompromised patients
- Induction tx: 5 mg/kg IV q12h x14-21 days; Info: not 1st-line agent
- Maintenance tx, IV route: 5 mg/kg IV 5-7x/wk; Alt: 6 mg/kg IV 5x/wk; Info: not 1st-line agent
- Maintenance tx, PO route: 1000 mg PO tid; Alt: 500 mg PO q3h while awake (6 doses/day); Info: not 1st-line agent; give with food
Pediatric Dosing
Off label use as pediatric medication
- CMV prophylaxis, solid organ transplant
- Induction: 5 mg/kg IV q12h x7-14 days
- Maintenance: 5 mg/kg IV q24h; Alt: 6 mg/kg IV 5x/wk
- CMV prophylaxis, HIV-assoc
- 5 mg/kg IV q24h
- CMV infection
- Induction: 5 mg/kg IV q12h x14-21 days; Info: may incr. dose to 7.5 mg/kg IV q12h
- Maintenance: 5 mg/kg IV q24h; Alt: 6 mg/kg IV 5x/wk
- CMV infection, congenital (<1 mo)
- 6 mg/kg IV q12h x6wk
Special Populations
Renal Dosing
- IV route, induction tx: CrCl 50-69: 2.5 mg/kg q12h; CrCl 25-49: 2.5 mg/kg q24h; CrCl 10-24: 1.25 mg/kg q24h; CrCl <10: 1.25 mg/kg 3x/wk; HD: give dose after dialysis, no supplement
- IV route, maintenance tx: CrCl 50-69: 2.5 mg/kg q24h; CrCl 25-49: 1.25 mg/kg q24h; CrCl 10-24: 0.625 mg/kg q24h; CrCl <10: 0.625 mg/kg 3x/wk; HD: give dose after dialysis, no supplement
- PO route: CrCl 50-69: 1500 mg/day divided qd-tid; CrCl 25-49: 1000 mg/day divided qd-bid; CrCl 10-24: 500 mg qd; CrCl <10: 500 mg 3x/wk; HD: give dose after dialysis, no supplement
Contraindications
- Allergy to class/drug
- hypersens. to acyclovir
- ANC <500
- Plt <25,000
Adverse Reactions
Serious
- thrombocytopenia
- neutropenia
- pancytopenia
- sepsis
- nephrotoxicity
- seizures
- retinal detachment
- HTN
- pancreatitis
Common
Pharmacology
- Half-life: 3hr
- Metabolism: CYP450
- Excretion: Urine
Mechanism of Action
Inhibits DNA polymerase and incorporates into viral DNA
Comments
See Also
References
Epocrates, UpToDate